Clinical Trial Update: Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating tasimelteon versus placebo for delayed sleep-wake phase disorder, including exploration of the CRY1Δ11 genetic variant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Circadian Rhythm Sleep-wake Disorder
• Delayed Sleep-wake Phase Disorder

Drugs mentioned

• Hetlioz (tasimelteon)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm | Phase 3 | Status: RECRUITING